We are live on ! Find out more
TRDA icon

Entrada Therapeutics
TRDA

97 hedge funds and large institutions have $481M invested in Entrada Therapeutics in 2024 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 42 increasing their positions, 18 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

175% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 8

133% more repeat investments, than reductions

Existing positions increased: 42 | Existing positions reduced: 18

110% more call options, than puts

Call options by funds: $551K | Put options by funds: $262K

17% more funds holding

Funds holding: 83 → 97 (+14)

14% more capital invested

Capital invested by funds: $423M → $481M (+$58.3M)

1.01% more ownership

Funds ownership: 79.9% → 80.91% (+1%)

0% more funds holding in top 10

Funds holding in top 10: 4 → 4 (0)

Holders
97
Holders Change
+14
Holders Change %
+16.87%
% of All Funds
1.39%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.06%
New
22
Increased
42
Reduced
18
Closed
8
Calls
$551K
Puts
$262K
Net Calls
+$289K
Net Calls Change
+$288K

Top Buyers

1
Janus Henderson Group
Janus Henderson Group
United Kingdom
+$2.55M
2
BlackRock
BlackRock
New York
+$2.03M
3
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$1.5M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$1.47M
5
Arrowstreet Capital
Arrowstreet Capital
Massachusetts
+$1.35M

Top Sellers

1
RG
Redmile Group
California
-$7.99M
2
American Century Companies
American Century Companies
Missouri
-$5.27M
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$1.35M
4
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$1.34M
5
SSA
Schonfeld Strategic Advisors
New York
-$1.16M
Name Holding Trade Value Shares
Change 		Change in
Stake
Morgan Stanley
26
Morgan Stanley
New York
$1.49M +$697K +44,215 +90%
Citadel Advisors
27
Citadel Advisors
Florida
$1.41M -$665K -42,225 -32%
Goldman Sachs
28
Goldman Sachs
New York
$1.35M +$806K +51,164 +154%
First Trust Advisors
29
First Trust Advisors
Illinois
$1.3M +$1.28M +81,549 New
Massachusetts Financial Services
30
Massachusetts Financial Services
Massachusetts
$1.11M +$1.09M +69,394 New
Acadian Asset Management
31
Acadian Asset Management
Massachusetts
$1.04M +$822K +52,156 +390%
CC
32
Corton Capital
Ontario, Canada
$924K +$45.3K +2,876 +5%
DM
33
Deerfield Management
New York
$916K +$903K +57,331 New
Manulife (Manufacturers Life Insurance)
34
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$909K -$3.83K -243 -0.4%
American Century Companies
35
American Century Companies
Missouri
$811K -$5.27M -334,248 -87%
TD Asset Management
36
TD Asset Management
Ontario, Canada
$786K -$371K -23,520 -33%
NFGH
37
Nan Fung Group Holdings
Hong Kong
$784K – – –
LPL Financial
38
LPL Financial
California
$781K +$770K +48,844 New
Barclays
39
Barclays
United Kingdom
$721K +$482K +30,585 +211%
Squarepoint
40
Squarepoint
New York
$664K +$246K +15,618 +60%
XT
41
XTX Topco
Cayman Islands
$634K +$625K +39,670 New
AQR Capital Management
42
AQR Capital Management
Connecticut
$631K +$622K +39,468 New
Lazard Asset Management
43
Lazard Asset Management
New York
$630K +$573K +36,359 +1,180%
SO
44
STRS Ohio
Ohio
$615K +$156K +9,900 +35%
Ameriprise
45
Ameriprise
Minnesota
$609K +$387K +24,560 +181%
MAM
46
Martingale Asset Management
Massachusetts
$606K +$161K +10,226 +37%
GCP
47
GSA Capital Partners
United Kingdom
$585K +$241K +15,284 +72%
RhumbLine Advisers
48
RhumbLine Advisers
Massachusetts
$580K -$10.1K -642 -2%
Bank of America
49
Bank of America
North Carolina
$544K +$80.8K +5,131 +18%
Los Angeles Capital Management
50
Los Angeles Capital Management
California
$542K +$535K +33,932 New
1
2
3 4 5

TRDA Hedge Fund Activity: Q3 2024 in Review

97 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Entrada Therapeutics (TRDA) for Q3 2024, worth a combined $481M — up 14% from $423M a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new TRDA positions and 8 closed out — a net gain of 14 holders — while 42 added to existing stakes and 18 trimmed.

The largest buyer was Janus Henderson Group, adding an estimated $2.55M. The largest seller was Redmile Group, exiting entirely with an estimated $7.99M sold.

  • 97 institutional investors held Entrada Therapeutics (TRDA) as of Q3 2024, up from 83 in Q2 2024.
  • Funds reported $481M of Entrada Therapeutics stock for Q3 2024, up 14% quarter-over-quarter.
  • 22 funds opened new Entrada Therapeutics positions in Q3 2024 and 8 closed out, a net change of +14 holders.
  • The largest Entrada Therapeutics buyer in Q3 2024 was Janus Henderson Group, an estimated $2.55M added.
  • The largest Entrada Therapeutics seller in Q3 2024 was Redmile Group, an estimated $7.99M sold.

Based on aggregated 13F filings for Q3 2024.